Merck & Co. vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q3 2026: Merck & Co. 18.085, Pfizer 16.583, Amgen 10.365, Roche 17.5245.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., Pfizer, Amgen, Roche.| Metric | Merck & Co. | Pfizer | Amgen | Roche |
|---|---|---|---|---|
| Market Cap | $362.27B | $164.33B | $252.64B | $386.08B |
| Revenue | $18.09B | $16.58B | $10.37B | $35.05B |
| Cost of Revenue | $4.89B | $4.03B | $2.79B | $9.21B |
| Gross Profit | $13.19B | $12.55B | $7.58B | $25.84B |
| Operating Income | $5.59B | $3.67B | $3.71B | $10.90B |
| Net Income | $5.07B | $3.24B | $3.86B | $7.93B |
| R&D Expense | $4.54B | $3.02B | $2.11B | $8.35B |
| Earnings Per Share | $2.04 | $0.56 | $7.08 | $1.23 |
| Gross Margin | 73.0% | 75.7% | 73.1% | 73.7% |
| Operating Margin | 30.9% | 22.1% | 35.8% | 31.1% |
| Net Profit Margin | 28.0% | 19.6% | 37.3% | 22.6% |
| Free Cash Flow | $5.52B | $4.80B | $3.65B | $6.46B |
| Cumulative Free Cash Flow | $255.22B | $361.51B | $172.83B | $305.80B |
| Operating Cash Flow | $6.56B | $5.38B | $4.24B | $8.28B |
| Cash & Equivalents | $9.55B | $1.82B | $13.19B | $6.13B |